Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

Sept. 22, 2020, 8:41 a.m. EDT

Vaccinex's stock falls after investigational drug fails Huntington's disease study

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Vaccinex Inc. (VCNX)
  • X
    Merck & Co. Inc. (MRK)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Vaccinex Inc. /zigman2/quotes/210125148/composite VCNX -4.02% tumbled 61.6% in premarket trading on Tuesday after the preclinical biotechnology company said an experimental Huntington's disease treatment, pepinemab, did not meet the primary endpoints in a Phase 2 double-blind, placebo-controlled clinical trial. Earlier this month, Vaccinex had announced plans to study pepinemab in combination with Merck & Co. Inc.'s /zigman2/quotes/209956077/composite MRK -1.88% Keytruda as a possible treatment for advanced forms of metastatic head and neck squamous cell carcinoma. Vaccinex's stock is up 12.8% so far this year. The S&P 500 /zigman2/quotes/210599714/realtime SPX -0.41% has gained 1.5%.

/zigman2/quotes/210125148/composite
US : U.S.: Nasdaq
$ 2.39
-0.10 -4.02%
Volume: 219,358
April 22, 2021 1:23p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$70.82 million
Rev. per Employee
$16,026
loading...
/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 77.74
-1.49 -1.88%
Volume: 6.75M
April 22, 2021 1:27p
P/E Ratio
27.95
Dividend Yield
3.35%
Market Cap
$200.48 billion
Rev. per Employee
$648,824
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,156.42
-17.00 -0.41%
Volume: 1.25B
April 22, 2021 1:27p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.